

## **Results baricitinib**

A greater improvement in SpO<sub>2</sub>/FiO<sub>2</sub> from hospitalization to discharge was observed in baricitinib-corticosteroids (BCT-CS) vs corticosteroids (CS) group (mean differences adjusted for IPSW, 49; 95% confidence interval [CI], 22 to 77;  $p<0.001$ ). A higher proportion of patients required supplemental oxygen both at discharge (62.0% vs 25.8%; reduction of the risk by 82%, OR adjusted for IPSW, 0.18; 95% CI, 0.08 to 0.43;  $p<0.001$ ) and one month later (28.0% vs 12.9%, reduction of the risk by 69%, OR adjusted for IPSW, 0.31; 95% CI, 0.11 to 0.86;  $p=0.024$ ) in CS vs BCT-CS group.